A 10-year budget impact simulation projects that integrating PromarkerD biomarker testing into routine type 2 diabetes care could delay kidney disease progression, reduce end-stage renal disease incidence, and generate net payer savings. The analysis estimates a 6.4% reduction in ESRD incidence and $1.2 billion in net savings per one million patients. The modeling framing emphasizes how risk stratification through biomarkers may shift downstream utilization patterns, positioning PromarkerD as a potential economic lever alongside clinical outcomes.